Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults (ESLIM-01 Study)

NCT05029635 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT05029635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults (ESLIM-01 Study)
Lead sponsor
Hutchmed
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2021
Completion date
September 18, 2025
Enrollment
272 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia (itp)